News Updates from KLCR
News
KENTUCKY CLINICAL TRIALS NETWORK
CURRENT STUDIES
Protocol No. |
Title |
Status |
|---|---|---|
AMGEN-20070782 |
Study to evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa administered at 500 ug once-every-three-weeks in Anemic subjects with Advanced Stage Non-small cell lung cancer receiving multi-cycle chemotherapy | Open |
| CTN-0501 | Randomized Phase II Trial of Carboplatin and Gemcitabine with or without Dexamethasone in Patients with Untreated Stage IIIB-pleural effusion and Stage IV Non-Small Cell Lung Cancer | Closed to Accrual |
| CTN-0601 | Lung Cancer Survival in Kentucky: A Multifactorial Approach | Open |
| GSK-MAGRIT | Phase III study to assess the efficacy of recMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resectable MAGE-A3-positive Non-Small Cell Lung Cancer | Closed to Accrual |
| H3E-US-S130 | Phase III Pemetrexed plus Carboplatin followed by Pemetrexed vs. Paciltaxel plus Carboplatin plus Bevacizumab followed by Bevacizumab in Advanced Non-small Cell Lung Cancer with Non-Squamous Histology" | Closed to Accrual |
| IMCLONE-CP11-0806 | Phase III study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab (IMC-11F8) Versus Gemcitabine-Cisplatin Chemotherapy Alone in the First-Line Treatment of Patients with Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) | Open |
| LUCANIX-BB-IND-8868 | Phase III Study of Lucanix(TM) as Maintenance Therapy for Patients with Stages III/IV NSCLC Who Have Responded to or Have Stable Disease Following One Regimen of Front-line Platinum-based Combination Chemotherapy | Open |
For additional information on study eligibility and to search for studies by treatment, disease type, and participating locations please click here: http://www.kctn.org/CurrentStudies/
To contact the KCTN Coordinating Center Team directly for study opportunities please click here: Kyclinicaltrialsnetwork@uky.edu
CONGRATULATIONS TO THE KLCR CYCLE 10 GRANT AWARD RECIPIENTS:
KLCR Cycle 10 Investigator-Initiated grants required investigators at the University of Louisville and the University of Kentucky to collaborate on projects that involve and engage the expertise at both institutions.
Jason Chesney, M.D., Ph.D. (UofL) and Younsoo Bae, Ph.D. (UK):"Controlled Inhibition of the Glycolytic Pathway for Lung Cancer-Targeted Therapy"
Teresa W.M. Fan, Ph.D. (UofL) and Rolf Joseph Craven, Ph.D. (UK): "Stable isotope-derived metabolomics to elucidate the mechanism of a tumor-associated cytochrome in lung cancer growth and metabolism"
Ramesh C. Gupta, Ph.D. (UofL) and Vivek M. Rangnekar, Ph.D. (UK): "Activation of the Par-4 Extrinsic Pathway for Suppression of Lung Cancer"
Goetz Kloecker, M.D. (UofL), Jun Yan, M.D. (UofL) and Edward A. Hirschowitz, M.D. (UK), John R. Yannelli, Ph.D. (UK): "Combined Orally Administered Yeast-derived β-Glucan with 1650 Tumor Vaccine in the Treatment of NSCLC"
W. Glenn McGregor, M.D. (UofL) and Zhigang Wang, Ph.D. (UK): "Rev1 and Carcinogen-Induced Lung Cancer"